Thrombosis research最新文献

{"title":"Barriers and facilitators to healthy lifestyle behaviours for people living with post pulmonary embolism syndrome. A qualitative study exploring participants lived experiences","authors":"Caoimhe Kenny ,&nbsp;Fiona Curran ,&nbsp;Olive Lennon ,&nbsp;Ann-marie O'Neill ,&nbsp;Frederikus A. Klok ,&nbsp;James Matthews ,&nbsp;Fionnuala Ni Ainle ,&nbsp;Rachel P. Rosovsky ,&nbsp;Grainne O'Donoghue ,&nbsp;Caoimhe Kenny","doi":"10.1016/j.thromres.2026.109625","DOIUrl":"10.1016/j.thromres.2026.109625","url":null,"abstract":"<div><h3>Background</h3><div>People living with post-pulmonary embolism syndrome (PPES) commonly experience persistent dyspnoea, fatigue, reduced exercise tolerance, anxiety, and fear of recurrence. When symptoms continue beyond three months after effective anticoagulation, quality of life can be substantially impaired. Although healthy lifestyle behaviours may improve PPES symptoms, little is known about the barriers and facilitators influencing behaviour change from the perspective of those affected.</div></div><div><h3>Aim</h3><div>To explore patients' perceived barriers and facilitators to adopting healthy lifestyle behaviours following PE, in order to inform the future development of rehabilitation interventions for people with PPES.</div></div><div><h3>Methodology</h3><div>A purposive sample of adults with PPES took part in semi-structured interviews informed by the Theoretical Domains Framework (TDF) and the Capability, Opportunity, Motivation–Behaviour (COM<img>B) model. Interviews were transcribed and analysed using a framework approach with inductive and deductive coding. Codes were grouped into categories and mapped to the 14 TDF domains and six COM-B constructs to identify behavioural influences and key barriers and facilitators.</div></div><div><h3>Findings</h3><div>Thirty-one participants (18 women, 13 men; aged 25–67 years) were interviewed. Ninety-eight codes were identified and organised into 35 categories, which were mapped to TDF and COM-B domains. The most frequently represented domains were Knowledge, Beliefs about Capabilities, Beliefs about Consequences, and Emotion. Key barriers and facilitators included pain, dyspnoea, healthcare professional knowledge and training, financial resources, and access to education and rehabilitation services.</div></div><div><h3>Conclusions</h3><div>Engagement in healthy lifestyle behaviours after PE is shaped by interacting physical, emotional, socioeconomic, and environmental factors. These findings highlight the need for comprehensive, theory-informed rehabilitation strategies that address both individual and contextual influences on behaviour change in people with PPES.</div></div>","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"259 ","pages":"Article 109625"},"PeriodicalIF":3.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147284965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evolving biomarkers and risk prediction models in colorectal cancer-associated venous thromboembolism","authors":"Lan Sun ,&nbsp;Jia Wang ,&nbsp;Yi-Dan Yan ,&nbsp;Long-Tu Li ,&nbsp;Lin-Yu Cao ,&nbsp;Ruo-Fei Li ,&nbsp;Shan Chong ,&nbsp;Meng Hu ,&nbsp;Hou-Wen Lin ,&nbsp;Yi-Min Cui ,&nbsp;Zhi-Chun Gu ,&nbsp;Qian Xiang","doi":"10.1016/j.thromres.2026.109619","DOIUrl":"10.1016/j.thromres.2026.109619","url":null,"abstract":"<div><div>The pathological hypercoagulable state and associated risk of thrombosis in colorectal cancer (CRC) persist throughout the disease course. Accurate identification of patients at high risk of venous thromboembolism (VTE) and judiciously applying drug or mechanical prevention measures can significantly reduce the incidence of VTE. The review details a range of biomarkers, including platelet count, soluble P-selectin, D-dimer, and vascular endothelial growth factor (VEGF), which have been shown to correlate with increased VTE risk in CRC patients. In addition to the biomarker analysis, the review makes important recommendations for the routine monitoring of these biomarkers in CRC patients, especially those at higher risk for VTE. Furthermore, it discusses the integration of these biomarkers into clinical VTE risk prediction models, advocating for personalized and targeted thromboprophylaxis strategies. The review also explores future research directions, emphasizing the potential of antiplatelet and anticoagulant therapies in improving the prognosis of CRC patients by reducing thromboembolic events. This narrative review not only deepens our understanding of the molecular mechanisms driving cancer-associated thrombosis but also paves the way for novel therapeutic interventions aimed at preventing VTE in CRC patients.</div></div>","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"259 ","pages":"Article 109619"},"PeriodicalIF":3.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146221222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"aPLs seroconversion in antiphospholipid syndrome: from definition to clinical relevance","authors":"Angela Di Giorgio ,&nbsp;Claudia Carnuccio ,&nbsp;Antonio Nesci ,&nbsp;Valerio De Stefano ,&nbsp;Angelo Santoliquido","doi":"10.1016/j.thromres.2026.109622","DOIUrl":"10.1016/j.thromres.2026.109622","url":null,"abstract":"<div><div>Antiphospholipid syndrome (APS) is an acquired coagulation disorder with an unclear pathogenesis, diagnosed in the presence of thrombotic events, obstetric complications, or non-thrombotic manifestations, alongside persistently detectable antiphospholipid antibodies. aPLs seroconversion, defined as the transition from persistent antibody positivity to sustained antibody negativity, is typically confirmed by at least two negative tests ≥12 weeks apart and maintained for over one year. This phenomenon is distinct from seronegative APS (SNAPS), in which patients present with APS-like clinical features but never fulfill laboratory criteria. Thrombotic risk remains significant in APS, particularly in patients with prior events or persistently elevated aPLs titers. Immunomodulatory therapies, such as hydroxychloroquine, rituximab, eculizumab, sirolimus, or other agents, may reduce antibody levels and contribute to improved outcomes, though evidence is limited. Among these, hydroxychloroquine is the most established agent, particularly in refractory or recurrent thrombotic cases, and is recommended as adjunctive therapy alongside anticoagulation in high-risk thrombotic and obstetric APS. While these therapies may allow cautious adjustments in anticoagulation for low-risk patients, anticoagulants should not be discontinued solely based on seroconversion or adjunctive treatment. Overall, immunomodulatory drugs should be considered strictly as adjuncts, with patient selection guided by clinical phenotype, thrombotic risk, and available evidence.</div></div>","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"259 ","pages":"Article 109622"},"PeriodicalIF":3.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146776650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rebuttal to correspondence on “Diagnostic accuracy meta-analysis of portal vein thrombosis imaging”","authors":"Laura Girardi ,&nbsp;Aurélien Delluc","doi":"10.1016/j.thromres.2026.109628","DOIUrl":"10.1016/j.thromres.2026.109628","url":null,"abstract":"","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"259 ","pages":"Article 109628"},"PeriodicalIF":3.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147310567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of body weight on clinical outcomes in cancer patients with low-risk pulmonary embolism receiving rivaroxaban: Insights from the ONCO PE trial","authors":"Toru Sato ,&nbsp;Yoshito Ogihara ,&nbsp;Yugo Yamashita ,&nbsp;Takeshi Morimoto ,&nbsp;Nao Muraoka ,&nbsp;Wataru Shioyama ,&nbsp;Ryuki Chatani ,&nbsp;Tatsuhiro Shibata ,&nbsp;Yuji Nishimoto ,&nbsp;Kosuke Doi ,&nbsp;Maki Oi ,&nbsp;Taro Shiga ,&nbsp;Daisuke Sueta ,&nbsp;Kitae Kim ,&nbsp;Yasuhiro Tanabe ,&nbsp;Norimichi Koitabashi ,&nbsp;Takuma Takada ,&nbsp;Satoshi Ikeda ,&nbsp;Hitoshi Nakagawa ,&nbsp;Kengo Tsukahara ,&nbsp;Kaoru Dohi","doi":"10.1016/j.thromres.2026.109631","DOIUrl":"10.1016/j.thromres.2026.109631","url":null,"abstract":"","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"259 ","pages":"Article 109631"},"PeriodicalIF":3.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147322205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The distinct etiology and imaging features of pediatric pulmonary embolism: dominance of Mycoplasma pneumoniae-associated in-situ thrombosis and severity risk stratification","authors":"Ruxuan He ,&nbsp;Xiaoyan Zhang ,&nbsp;Xiaolei Tang ,&nbsp;Yuelin Shen ,&nbsp;Hui Liu ,&nbsp;Jinrong Liu ,&nbsp;Huimin Li ,&nbsp;Shunying zhao ,&nbsp;Haiming Yang","doi":"10.1016/j.thromres.2026.109597","DOIUrl":"10.1016/j.thromres.2026.109597","url":null,"abstract":"<div><h3>Background</h3><div>Pediatric pulmonary embolism (PE) incidence has shown a steady rise in recent years, underscoring a distinct and evolving etiological landscape. Infection-related PE, notably <em>Mycoplasma pneumoniae</em> (MPP), now accounts for an increasing proportion of pediatric PE cases, raising questions about a distinct in-situ thrombosis (ISPAT) pathophysiology. We aimed to systematically characterize the etiological spectrum of childhood PE and identify independent predictors of severe disease.</div></div><div><h3>Methods</h3><div>We conducted a 6-year retrospective cohort study of 113 pediatric PE pediatric patients diagnosed with PE at Department No.2 of Respiratory Medicine, Beijing Children's Hospital, from June 2018 to June 2024. Data included clinical and imaging findings, underlying conditions, and outcomes. Predictors of severe PE were assessed using multivariable logistic regression.</div></div><div><h3>Results</h3><div>The median age was 8.37 years. Infection was the leading etiology (89.4%), most commonly MPP (88.1%). Computed tomography pulmonary angiography (CTPA) revealed emboli were predominantly subsegmental/peripheral (80.5%), supporting the ISPAT phenotype. Post-infectious pulmonary vasculitis was identified in 8 patients, with NOD2, MPEG1, or CYBB variants detected in 3 cases. On multivariable analysis, infection−associated PE was independently linked to lower odds of severe PE (adjusted OR 0.12, 95% CI 0.03–0.54; <em>p</em> = 0.0055).</div></div><div><h3>Conclusion</h3><div>Pediatric PE is predominantly an ISPAT phenomenon driven by MPP-associated immunothrombosis. The distinct thrombotic pattern and better prognosis in the infection group support etiology based risk stratification. Furthermore, the observed links with post-infectious vasculitis and variants in NOD2, MPEG1, or CYBB suggest that occult immune dysregulation may modulate thrombotic risk in susceptible children.</div></div>","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"259 ","pages":"Article 109597"},"PeriodicalIF":3.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146057466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mild hemophilia B in a female with compound heterozygous FIX variants presented with abdominal pain and diagnosed with nutcracker syndrome, and median arcuate ligament syndrome","authors":"Davut Ünsal Çapkan ,&nbsp;Asmin Çelik ,&nbsp;Uğur Gümüş ,&nbsp;İbrahim Tayfun Şahiner ,&nbsp;Ekrem Ünal","doi":"10.1016/j.thromres.2026.109594","DOIUrl":"10.1016/j.thromres.2026.109594","url":null,"abstract":"","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"259 ","pages":"Article 109594"},"PeriodicalIF":3.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146081687","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"von Willebrand factor in hemodialysis patients. Does acquired von Willebrand syndrome occur?","authors":"Michele Marchini","doi":"10.1016/j.thromres.2026.109636","DOIUrl":"10.1016/j.thromres.2026.109636","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Introduction and aims&lt;/h3&gt;&lt;div&gt;von Willebrand factor (vWF) is a multimeric plasma glycoprotein synthesized by endothelial cells and megakaryocytes that has an essential role in the primary hemostasis, in fact, the high-molecular-weight multimers (HMWMs) of vWF are the most effective in mediating platelet binding to the extracellular matrix. Acquired von Willebrand syndrome (AvWS) is a bleeding disorder characterized by the loss of HMWMs of vWF with consequent impaired vWF binding to platelets.&lt;/div&gt;&lt;div&gt;Specific hemodynamic conditions of high vascular shear stress and immunologic diseases are linked to the development of this syndrome. Data on vWF function and its multimeric pattern in maintenance hemodialysis patients are scant and inconsistent.&lt;/div&gt;&lt;div&gt;The aim of this study was to investigate the potential development of biochemical markers of AvWS and to preliminarily explore whether the reduction of HMWMs may be associated with an increased risk of bleeding.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;Sodium citrate plasma was collected from 53 hemodialysis patients (HP) and 25 healthy control subjects (C). Plasma levels of von Willebrand factor Antigen (vWF:Ag) were measured, and vWF functional activity was assessed by evaluating its Ristocetin cofactor activity (vWF:Rcof).&lt;/div&gt;&lt;div&gt;A vWF:Rcof/vWF:Ag ratio of &lt;0.7 was considered indicative of dysfunctional vWF.&lt;/div&gt;&lt;div&gt;von Willebrand Multimers were separated using sodium dodecyl sulfate (SDS)-agarose low-resolution gels and blotted onto a nitrocellulose membrane. Multimer separation was performed based on electrophoretic mobility. Multimers were detected immunologically using rabbit anti-human-vWF antibodies. Densitometric analysis of multimers and quantification of the percentage of different electrophoretic areas were performed using ImageJ software (NIH, USA). Acquired von Willebrand syndrome (AvWS) was diagnosed if the vWF:Rcof/vWF:Ag ratio was below the normal range (&lt;0.7) and densitometric analysis revealed a reduction HMWMs in hemodialysis patients (HP) compared to controls (C). To quantitatively estimate HMWMs loss, a control-derived threshold was established based on the 5th percentile of the control population (9%). Bleeding events in hemodialysis patients were retrospectively collected from the initiation of dialysis and classified according to ISTH criteria. Corresponding HMWMs levels and vWFRcof/vWF:Ag ratio values were analyzed by means of binary logistic regression. Statistical analysis was performed using MedCalc software (MedCalc Software Ltd., Ostend, Belgium). The alpha value for statistical significance was set at 0.05.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;vWF:Ag levels were higher in HP compared to controls 169.3% (77.9–238.0) vs. 120.8% (82.3–141.6); &lt;em&gt;p&lt;/em&gt; = 0.017. Hemodialysis patients (HP) exhibited also lower vWF:Rcof values to Controls, but this difference was not statistically significant 88.7% (30–148.2) vs. 105.2% (96.1–113.6); &lt;em&gt;p&lt;/em&gt; = 0.16","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"259 ","pages":"Article 109636"},"PeriodicalIF":3.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147356583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A real-world evaluation of the safety of edoxaban in frail older adults with non-valvular atrial fibrillation","authors":"Alvaro Hermida-Ameijeiras ,&nbsp;Nestor Vazquez-Agra ,&nbsp;Carlos Rodriguez-Pascual ,&nbsp;Bernardo-Abel Cedeno-Veloz ,&nbsp;Ramon Baeza-Trinidad ,&nbsp;Pablo Solla-Suarez ,&nbsp;Juan-Bosco Lopez-Saez ,&nbsp;Ricardo Gomez-Huelgas ,&nbsp;Santiago-Jesus Freire-Castro ,&nbsp;Alicia Balanza-Garzon ,&nbsp;Cristina Roqueta ,&nbsp;Antonio Pose-Reino","doi":"10.1016/j.thromres.2026.109614","DOIUrl":"10.1016/j.thromres.2026.109614","url":null,"abstract":"<div><h3>Background</h3><div>Despite available observational data and post hoc analyses, the underprescription of DOACs in frail older adults and their underrepresentation in randomized trials have resulted in a still limited evidence base.</div></div><div><h3>Objective</h3><div>To evaluate the safety of edoxaban in frail older patients in routine clinical practice in Spain.</div></div><div><h3>Materials and methods</h3><div>EDO-FRAG-001 was a multicenter, prospective, observational, real-world, single-cohort study with 12 months of follow-up. Patients aged ≥75 years with non-valvular atrial fibrillation (NVAF), a FRAIL scale score between 3 and 5, and those who initiated edoxaban within the previous 6 months were enrolled.</div></div><div><h3>Results</h3><div>A total of 411 patients (63% women) were included, with a median age of 87 years. Fifty-five percent had previously received vitamin K antagonists. Edoxaban was prescribed according to the drug label in 89.1% of patients. During follow-up, 31 patients experienced major bleeding events [annualized rate: 8.7% (95% CI: 5.8–11.6)], and 5 individuals developed an ischemic stroke or systemic embolism [1.1% (95% CI: 0.1–2.2)]. One-year all-cause mortality was 18.8% (95% CI: 15.1–22.5), and cardiovascular mortality accounted for 8.7% (95% CI: 6.2–11.2). The incidence of bleeding-related death was 2.0% (95% CI: 0.5–3.5).</div></div><div><h3>Conclusion</h3><div>This real-world study supports that the use of edoxaban in frail older adults with NVAF is associated with an acceptable rate of bleeding and stroke. Age and frailty alone should not preclude anticoagulation when treatment is carefully individualized.</div></div>","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"259 ","pages":"Article 109614"},"PeriodicalIF":3.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146166765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Venous thromboembolism prevention in ambulatory oncology: A multi-method evaluation of the Vermont Model to inform adaptation to an oncology-delivered model","authors":"Karlyn A Martin ,&nbsp;Emily Hallgren ,&nbsp;Chris E Holmes ,&nbsp;Jacob Barker ,&nbsp;Lisa R. Hirschhorn ,&nbsp;Kenzie A. Cameron","doi":"10.1016/j.thromres.2026.109610","DOIUrl":"10.1016/j.thromres.2026.109610","url":null,"abstract":"<div><h3>Background</h3><div>Despite evidence-based guidelines, venous thromboembolism (VTE) prevention in ambulatory cancer remains low. The “Vermont Model” is a multidisciplinary program wherein oncology nurses conduct VTE risk assessment, VTE patient-education to all patients starting anti-cancer therapy and refer high risk patients to thrombosis specialist to discuss thromboprophylaxis. The Vermont Model successfully improved targeted anticoagulation prophylaxis for high-risk patients, but efforts to reproduce the model in community oncology practices were less successful. The objective of this study was to evaluate stakeholder (clinician and patient) perceptions of the Vermont Model to inform adaptation to a fully oncology-delivered approach.</div></div><div><h3>Methods</h3><div>We conducted a concurrent multi-method study from September 2024–January 2025, including a clinician survey assessing normalizing of the Vermont Model into clinical practice and semi-structured interviews of participating clinicians and patients.</div></div><div><h3>Results</h3><div>Ten clinicians and four patients completed interviews. Based on 9 clinician surveys, the Vermont Model is normalized into practice. Factors important to its success reflected in both the survey and interviews data included a strong culture valuing VTE prevention and a local champion. Participants supported a fully oncology-delivered model, yet challenges to success include lapses in intervention education/training, communication among health care team, and relative priority with existing workload.</div></div><div><h3>Conclusion</h3><div>We found high normalization of the Vermont Model among participating clinicians and highlight opportunities to enhance training, education, and interprofessional communication to scale out to a fully oncology-delivered model.</div></div>","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"259 ","pages":"Article 109610"},"PeriodicalIF":3.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146137848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}